The European Journal of Preventive Cardiology, published by Oxford University Press, is a leading international journal dedicated to the field of cardiology and cardiovascular medicine. With an impact factor that underscores its prestige—ranking in the top quartile (Q1) of both cardiology and epidemiology categories—the journal serves as a critical resource for researchers and practitioners seeking to advance their understanding of preventive strategies in cardiovascular health. Since its inception in 1999, it has provided a platform for high-quality research and reviews that address the epidemiology of cardiovascular diseases, risk factor management, and innovative prevention methodologies. Notably, it currently ranks #21 out of 387 in Medicine - Cardiology and #13 out of 148 in Medicine - Epidemiology according to Scopus, highlighting its influential position in these essential biomedical fields. The journal also provides open access options, allowing both readers and authors the opportunity to engage with groundbreaking research and enhance the dissemination of knowledge. With a commitment to excellence, the European Journal of Preventive Cardiology is an invaluable asset for those dedicated to the prevention of cardiovascular diseases.

Frontiers in Cardiovascular Medicine is a leading open-access journal published by FRONTIERS MEDIA SA, dedicated to advancing research in the field of cardiology and cardiovascular medicine. Since its inception in 2014, the journal has become a vital platform for the dissemination of high-quality research, boasting a commendable Q2 rank in the 2023 category for Cardiology and Cardiovascular Medicine. With a focus on promoting innovative studies and clinical insights, Frontiers in Cardiovascular Medicine facilitates open access to its content, allowing researchers, healthcare professionals, and students from around the globe to engage with the latest findings which are critical for the advancement of cardiovascular health. The journal's significant presence in the academic landscape, as indicated by its Scopus ranking (161/387 and 58th percentile), underscores its importance as a research outlet in this essential field. Located in Lausanne, Switzerland, the journal continues to support the global cardiovascular community by encouraging collaboration and knowledge sharing to address the challenges faced in cardiovascular medicine today.

HEART is a leading peer-reviewed journal published by the BMJ Publishing Group, specializing in the field of Cardiology and Cardiovascular Medicine. Established in 1942, the journal has evolved as a premier platform for disseminating high-quality research, innovative practices, and clinical advancements within the cardiovascular domain. With an impressive impact factor and ranked in the Q1 category in 2023, it positions itself among the top-tier journals in its field, boasting a Scopus rank of #37 out of 387 in this highly competitive area, representing the top 10th percentile nationally. The journal supports both traditional and open access options, thereby enhancing the global visibility and reach of its published work. Researchers, professionals, and students alike will find HEART to be an invaluable resource, offering the latest insights and developments that drive the field forward and improve patient care worldwide.

JAMA Cardiology, published by the American Medical Association, is a leading peer-reviewed journal in the field of cardiology and cardiovascular medicine, with an impressive impact factor signifying its influence and relevance within the medical community. Established in 2016, this journal has quickly gained recognition, currently positioned in the Q1 quartile and ranked #2 out of 387 in its field according to Scopus, reflecting its commitment to high-quality research dissemination. As an esteemed publication, JAMA Cardiology aims to advance the understanding of cardiovascular health through rigorous studies, reviews, and clinical insights. The journal is dedicated to serving a diverse audience of researchers, clinicians, and students, ensuring they have access to groundbreaking findings and comprehensive discussions that shape contemporary cardiology. Although it is not an open-access journal, articles published within it play a pivotal role in informing clinical practice and guiding future research in cardiovascular health, making it an essential resource for anyone engaged in this vital field.

COR ET VASA is a prominent peer-reviewed journal in the field of cardiology and cardiovascular medicine, published by the Czech Society of Cardiology and Czech Society of Cardiovascular Surgery. Established in 1961, and continuing its legacy from 2006 to 2024, this journal serves as an essential platform for disseminating significant research findings, clinical studies, and innovative treatments in cardiovascular health. While currently positioned in the Q4 quartile, the journal aims to enhance its impact by fostering knowledge sharing among researchers, clinicians, and students alike. The journal, with its publication in Czech Republic, provides a unique perspective to the European cardiovascular community, allowing for invaluable insights and discourse. Researchers are encouraged to submit their manuscripts and contribute to the growing body of knowledge in this critical area, although it should be noted that COR ET VASA does not offer open access options at this time. As the field of cardiovascular medicine evolves, COR ET VASA remains committed to addressing the latest challenges and advancements, nurturing a rich dialogue within the community.

Cardiovascular Therapeutics is a renowned Open Access journal, published by WILEY-HINDAWI, that has been at the forefront of advancing knowledge in the field of cardiology and cardiovascular medicine since its establishment. With a strong commitment to disseminating high-quality research, the journal has successfully positioned itself within the Q2 quartile in multiple categories, including Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), and Pharmacology. The journal is indexed in Scopus, achieving impressive rankings, such as #95 out of 387 in Cardiology, and #87 out of 272 in Medical Pharmacology. Situated in the United Kingdom, Cardiovascular Therapeutics embraces an Open Access model since 2019, ensuring that groundbreaking research is accessible to researchers, practitioners, and students across the globe. The journal is dedicated to publishing original research articles, reviews, and clinical studies that contribute to the understanding and treatment of cardiovascular diseases, making it an essential resource for those invested in improving patient outcomes and advancing therapeutic strategies in this vital area of medicine.

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.

Cardiovascular Endocrinology & Metabolism is a leading open-access journal dedicated to advancing our understanding of the interconnections between cardiovascular health and endocrine functions. Published by Lippincott Williams & Wilkins, this journal serves as a vital resource for researchers and clinicians alike, providing timely insights into the intricate relationships between metabolic disorders and cardiovascular diseases. With an impressive impact factor and categorized in Q2 for both Cardiology and Cardiovascular Medicine as well as Endocrinology, Diabetes, and Metabolism, it holds a significant position within its respective fields. The journal has been fully open access since its inception in 2012, ensuring that critical research is accessible to a global audience. By fostering innovation and collaboration, Cardiovascular Endocrinology & Metabolism aims to promote better health outcomes and stimulate novel research directions, making it an essential resource for professionals striving to bridge the gaps between these two critical domains.

World Journal of Cardiology, published by BAISHIDENG PUBLISHING GROUP INC, stands out as a pivotal resource in the field of cardiology and cardiovascular medicine. With an ISSN of 1949-8462, this journal serves a global audience, promoting knowledge dissemination and collaboration among researchers, healthcare professionals, and students dedicated to advancing cardiovascular health. The journal demonstrates its credibility and impact in the field by achieving a respectable Q2 ranking in the 2023 category of Cardiology and Cardiovascular Medicine. Notably, it is listed in the Scopus database, ranking #189 out of 387 journals, placing it in the 51st percentile, which underscores its relevance and contribution to contemporary cardiovascular research. Although it operates under a subscription model, the journal provides diverse access options, ensuring that critical findings reach a wide audience. Through its comprehensive scope and commitment to publishing high-quality articles, the World Journal of Cardiology plays a vital role in shaping the future of cardiovascular science, making it an invaluable asset for those involved in this essential discipline.

International Cardiovascular Research Journal, published by Shiraz University Medical Sciences, serves as a vital platform for the dissemination of cutting-edge research in the field of cardiology and cardiovascular medicine. Since its inception in 2011, this journal has continuously devoted itself to promoting the highest quality of scholarly communication, helping to bridge the gap between laboratory findings and clinical application. With an ISSN of 2251-9130 and an E-ISSN of 2251-9149, it is indexed in prominent databases, contributing to its visibility and accessibility to a global audience. Although currently classified in the Q4 quartile in the 2023 rankings, the journal is committed to enhancing its impact factor and academic stature. It aims to facilitate open access for all published articles, although specific details on access options are pending. Through its rigorous peer-review process and diverse scope—which encapsulates advancements, clinical studies, and innovative therapeutic strategies—this journal fosters academic collaboration in the realm of cardiovascular health, making it an invaluable resource for researchers, practitioners, and students alike.